Pharmaceutical

Notice Regarding the First Patient Dosed in the Phase I/II company-sponsored Clinical Trial of HS-005 (Catheter Administration) for Cardiac Remuscular

Notice Regarding the First Patient Dosed in the Phase I/II company-sponsored Clinical Trial of HS-005 (Catheter Administration) for Cardiac Remuscular

articleHeartseed, Inc.June 12, 20263/news/notice-regarding-the-first-patient-dosed-in-the-phase-iii-company-sponsored-clinical-trial-of-hs-005-catheter-administration-for-cardiac-remuscular
Notice Regarding the First Patient Dosed in the Phase I/II company-sponsored Clinical Trial of HS-005 (Catheter Administration) for Cardiac Remuscular

About this update from Heartseed, Inc.

Heartseed, Inc. (219A) Press ReleaseView Attachment

View stock analysis, news, and events for Heartseed, Inc.